Clinical PGx Education
We will review the use of pharmacogenomic tests in five therapeutic areas:
Within each therapeutic area, we will include the following:
The gene or allele of interest
The functional effect of the gene or allele
The prevalence of the relevant alleles in various populations
The available genomic tests
A summary of the most significant clinical data available to date, regarding
Drug dosing and selection
And finally, recommendations for genomic testing from reputable agencies or national guidelines.
Click links to view video:
Russ Altman, MD, PhD
Kenneth Fong Professor and Professor of Bio-engineering, of Genetics, of Medicine – Stanford School of Medicine
DNA methylation is a process by which methyl groups are added to DNA. Methylation modifies the function of the DNA, typically acting to suppress gene transcription. DNA methylation is essential for normal development and is associated with a number of key processes including genomic imprinting, X-chromosome inactivation, suppression of repetitive elements, and carcinogenesis.
Mary V. Relling, Pharm.D. joined St. Jude as a faculty member in 1988, and in 2003 was named chair of the Department of Pharmaceutical Sciences. She is also a professor at The University of Tennessee in the colleges of Medicine and Pharmacy. Her primary interests are in treatment of childhood leukemia and pharmacogenetics of anti-leukemic therapy. Dr. Relling is one of the principal investigators within the National Institutes of Health Pharmacogenomics Research Network and co-founder of the Clinical Pharmacogenetics Implementation Consortium.
Applied pharmacogenomics resolves patient’s lifelong anxiety and depression.
University of Alabama at Birmingham – Hugh Kaul Personalized Medicine Institute